Injury:骨髓炎经诱导膜技术治疗后复发的风险因素分析

2020-12-03 MedSci原创 MedSci原创

一项回顾性研究观察了诱导膜技术治疗四肢骨髓炎的疗效,并分析感染复发的原因及其危险因素,研究结果已在线发表于Injury。

一项回顾性研究观察了诱导膜技术治疗四肢骨髓炎的疗效,并分析感染复发的原因及其危险因素,研究结果已在线发表于Injury

研究纳入2013年5月至2017年6月采用引膜技术治疗的424例四肢骨髓炎患者。收集、总结、分析感染复发时间、复发部位及其他相关资料。

 

共有424例患者经一期骨髓炎治疗后视为 "痊愈",并进行诱导膜技术重建骨缺损。平均随访31.6(16~63)个月后,52例患者感染复发,其中胫骨42例,股骨10例,复发率为12.26%。16例患者经静脉抗生素治疗后症状缓解。其余36例(8.49%)经静脉抗生素治疗后感染无法控制,进行手术清创。胫骨感染的复发率(16.22%)高于股骨(8.70%)。外伤后骨髓炎的复发率(14.66%)明显高于血源性骨髓炎(2.41%)。初期分离出铜绿假单胞菌的患者复发率为28%(7/25),高于其他分离菌的复发率。Logistic回归分析显示,重复手术(≥3次)、创伤性骨髓炎、I期内固定是感染复发的危险因素,OR分别为2.30、5.53、5.28。

综上所述,该研究结果表明,诱导膜技术是治疗四肢骨髓炎的有效方法,但部分病例会复发感染。反复手术、创伤后骨髓炎、I期内固定是感染复发的危险因素。第一阶段分离出的绿脓杆菌、胫骨骨髓炎、存在窦道或皮瓣也可能与感染的复发有关。

 

原始出处:

 

Xiaohua Wang, Shulin Wang, et al., Risk factors associated with recurrence of extremity osteomyelitis treated with the induced membrane technique. Injury . 2020 Feb;51(2):307-311. doi: 10.1016/j.injury.2019.11.026. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1877913, encodeId=390f18e7913bc, content=<a href='/topic/show?id=d21b9864ab' target=_blank style='color:#2F92EE;'>#Injury#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9864, encryptionId=d21b9864ab, topicName=Injury)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Tue Nov 02 21:25:11 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810662, encodeId=36151810662eb, content=<a href='/topic/show?id=d658858334a' target=_blank style='color:#2F92EE;'>#膜技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85833, encryptionId=d658858334a, topicName=膜技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Apr 11 21:25:11 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374611, encodeId=0b2d13e461126, content=<a href='/topic/show?id=cade101985bd' target=_blank style='color:#2F92EE;'>#骨髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101985, encryptionId=cade101985bd, topicName=骨髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Dec 05 14:25:11 CST 2020, time=2020-12-05, status=1, ipAttribution=)]
    2021-11-02 xuqianhua
  2. [GetPortalCommentsPageByObjectIdResponse(id=1877913, encodeId=390f18e7913bc, content=<a href='/topic/show?id=d21b9864ab' target=_blank style='color:#2F92EE;'>#Injury#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9864, encryptionId=d21b9864ab, topicName=Injury)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Tue Nov 02 21:25:11 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810662, encodeId=36151810662eb, content=<a href='/topic/show?id=d658858334a' target=_blank style='color:#2F92EE;'>#膜技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85833, encryptionId=d658858334a, topicName=膜技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Apr 11 21:25:11 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374611, encodeId=0b2d13e461126, content=<a href='/topic/show?id=cade101985bd' target=_blank style='color:#2F92EE;'>#骨髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101985, encryptionId=cade101985bd, topicName=骨髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Dec 05 14:25:11 CST 2020, time=2020-12-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1877913, encodeId=390f18e7913bc, content=<a href='/topic/show?id=d21b9864ab' target=_blank style='color:#2F92EE;'>#Injury#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9864, encryptionId=d21b9864ab, topicName=Injury)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Tue Nov 02 21:25:11 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810662, encodeId=36151810662eb, content=<a href='/topic/show?id=d658858334a' target=_blank style='color:#2F92EE;'>#膜技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85833, encryptionId=d658858334a, topicName=膜技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Apr 11 21:25:11 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374611, encodeId=0b2d13e461126, content=<a href='/topic/show?id=cade101985bd' target=_blank style='color:#2F92EE;'>#骨髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101985, encryptionId=cade101985bd, topicName=骨髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Dec 05 14:25:11 CST 2020, time=2020-12-05, status=1, ipAttribution=)]
    2020-12-05 宋威